Ilyang Pharmaceutical ,Ltd EBIT

The latest EBIT for 007570.KS is $-39B as of June 2026. That compares with $39B in the prior-year period — down 202.0% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Ilyang Pharmaceutical ,Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, 007570.KS's EBIT moved from $39B to $-39B — a 202.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ilyang Pharmaceutical ,Ltd's operating scale or balance-sheet position.

Against its sector companies, 007570.KS currently prints $-39B for EBIT, while the sector average sits near $2.6T. That is roughly 101.5% below the sector mean. Large gaps often invite a closer look at Ilyang Pharmaceutical ,Ltd's growth, margins, and balance sheet.

A EBIT figure of $-39B for 007570.KS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 007570.KS's EBIT ($-39B), review year-over-year change from $39B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.